Faster global financial news!
Novo Nordisk
-
Novo Nordisk's stock slumped after announcing a Phase 3 trial failure.
Novo Nordisk's stock slumped after announcing a Phase 3 trial failure.
-
Analysis: Novo Nordisk's New Weight-Loss Drugs Face Efficacy Challenges Against Eli Lilly
A recent analysis indicates that Novo Nordisk's stock has fallen 29% over the past 12 months, as its new weight-loss drug candidates face stiff competition from Eli Lilly. Novo Nordisk's CagriSema, a
-
Novo Nordisk's next-generation obesity drug CagriSema showed an average weight reduction of 25% in women in a late-stage analysis.
Danish pharmaceutical giant Novo Nordisk on Tuesday released updated late-stage analysis data for its next-generation experimental obesity drug, CagriSema. The results showed that among approximately
-
Denmark's financial regulator stated that the country's economic growth is expected to slow as the pharmaceutical boom led by Novo Nordisk loses momentum.
Denmark's financial regulator stated that the country's economic growth is expected to slow as the pharmaceutical boom led by Novo Nordisk loses momentum.
-
Novo Nordisk seeks national health insurance coverage for Wegovy in Korea
Novo Nordisk Korea has applied to the Health Insurance Review and Assessment Service for reimbursement of its obesity drug Wegovy, pharmaceutical industry sources said Tuesday. This move aims to signi
-
Novo Nordisk's amylin analog drug CagriSema is expected to launch early next year, with new data showing it can reduce "food noise."
Novo Nordisk's amylin drug CagriSema is expected to launch early next year, with the standalone cagrilintide and high-dose CagriSema anticipated in 2028. New data released by Novo Nordisk this week sh
-
Hengrui Pharmaceuticals licenses oral weight-loss drug HRS-1596 to Novo Nordisk in a potential $2.6 billion deal.
China's Hengrui Pharmaceuticals announced it has licensed its self-developed oral GLP-1/GIP dual receptor agonist, HRS-1596, to Novo Nordisk, a global leader in weight-loss drugs, for all global marke
-
Novo Nordisk unveils new growth strategy, but analysts remain skeptical about the market prospects of its GLP-1 drugs.
Novo Nordisk unveiled a strategy this week aimed at revitalizing growth, planning to diversify its product pipeline to drive expansion after the patents for its blockbuster drugs Wegovy and Ozempic ex
-
Swedish microcap Nanexa shares soar over 150% after striking $1.33 billion injectables deal with Novo Nordisk
The drug-delivery group will receive an upfront payment of $700 million and potential milestone payments for its PharmaShell technology. This technology will be used in Novo Nordisk's long-acting inje
-
Ozempic-maker Novo open to upgrading US listing
Ozempic-maker Novo is open to upgrading its US listing, with boss Mike Doustdar stating he sees advantages in giving US investors direct access to the Danish group’s stock.
-
Novo Nordisk CEO signals M&A opportunities to strengthen drug pipeline amid competition
Novo Nordisk CEO Mike Doustdar told CNBC on Tuesday that the pharmaceutical giant is considering M&A opportunities to strengthen its drug pipeline, as it faces growing competition in the weight-loss m
-
Novo Nordisk, the Danish pharmaceutical giant, saw its shares fall by 7% despite setting a $23 billion sales target for its weight-loss drug.
Novo Nordisk's share price fell by as much as 7% on Monday after the company unveiled new growth ambitions aimed at reinvigorating its position in the booming obesity drug market. The company plans to
-
Ozempic Maker Novo Nordisk Investors Call for Diversification Through Deals, New Drugs
Ozempic maker Novo Nordisk is facing diversification pressure as the company meets with shareholders on Monday.
-
Novo Nordisk partners with Anthropic to accelerate AI drug discovery; ByteDance's AI drug discovery company, Anew Labs, completes $290 million in financing; A-share innovative drug and CRO sectors are active.
Danish pharmaceutical company Novo Nordisk announced on September 16 its partnership with Anthropic, leveraging its scientific platform Claude Science to accelerate new drug discovery. On the same day
-
Yahoo Finance analysts recommend three undervalued growth stocks: Novo Nordisk, Intuit, and Reddit.
Yahoo Finance analysts recommend three undervalued growth stocks—Novo Nordisk (NVO), Intuit (INTU), and Reddit (RDDT)—believing they have significant growth potential at their current valuations. Novo
-
Novo Nordisk's Wegovy shows positive results in child obesity trial, but market adoption faces hurdles; shares down 17% over past year
Novo Nordisk's (NYSE:NVO) Phase 3 STEP Young trial for its obesity drug semaglutide (Wegovy) showed positive results in children aged six to under twelve, with a meaningful share moving below the clin
-
Yahoo Finance analysis recommends Regeneron Pharmaceuticals (REGN) over Novo Nordisk (NVO) for 2026, citing strong recent performance across all major drugs.
The analysis highlights Regeneron's robust Q2 2026 performance, with record sales for Dupixent, EYLEA HD, and Libtayo, and a significant beat on earnings estimates. The company also expanded its pipel
-
Yahoo Finance Analysts: AbbVie's Net Profit Expected to Soar to $14.6 Billion by 2026, While Novo Nordisk's Sales May Decline by 3%
Yahoo Finance analysts compared the financial performance and 2026 outlook for healthcare companies AbbVie and Novo Nordisk. The analysis indicates that AbbVie reported revenues of $61.2 billion and n
-
Analysis: Novo Nordisk stock 'too cheap to ignore' after 66%+ drop from 2024 high, despite Eli Lilly GLP-1 competition
The Motley Fool analysis suggests that after Novo Nordisk's stock declined over 66% from its 2024 high, traditional valuation metrics like price-to-sales (4x vs 5-year average 8.6x) and price-to-earni
-
Denmark raises 2026 economic growth forecast for fourth time, mainly boosted by Novo Nordisk's weight-loss drug Wegovy
Denmark raises 2026 economic growth forecast for fourth time, mainly boosted by Novo Nordisk's weight-loss drug Wegovy
-
Deutsche Bank downgrades Ozempic maker Novo Nordisk to sell after 70% stock-price dive from peak
Deutsche Bank downgrades Ozempic maker Novo Nordisk to sell after 70% stock-price dive from peak
-
Eli Lilly's Q2 revenue grew by 48%, and it plans to submit a BLA for its weight-loss drug Retatrutide in Q1 2027; Novo Nordisk, on the other hand, laid off 12,000 employees.
Eli Lilly reported a 48% increase in Q2 2026 revenue and raised its full-year guidance. Its weight-loss drugs, Mounjaro and Zepbound, generated a combined $14.9 billion in sales in Q2, capturing appro
-
Novo Nordisk Establishes Strategic Collaboration with Amazon AWS to Accelerate Drug Discovery and Modernize Operations with AI and Cloud Technologies
The agreement establishes Amazon AWS as Novo Nordisk's preferred cloud provider and strategic AI partner. The two companies have also established a joint innovation center in London, where AWS enginee
-
Eli Lilly (LLY) stock rose 3.37% to $1223.04, narrowing the early lead of Novo Nordisk in the weight-loss drug market.
Eli Lilly's stock price has rebounded from its 50-day moving average and is currently above its 21-day and 10-day moving averages, demonstrating strong market performance. The company is challenging N
-
Novo Nordisk stock falls after Wegovy pill's 'surprise miss', despite improved full-year outlook
Novo Nordisk stock falls after Wegovy pill's 'surprise miss', despite improved full-year outlook
-
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
- No data
Novo Nordisk
24H Trending
-
1
What is FLOW? An Analysis of the Flow Blockchain Ecosystem and Its Current Status
-
2
Report: Hedge Funds Exit Bitcoin ETF Arbitrage Trades, Sovereign Wealth Funds and Retail Investors Step In
-
3
LS Cable subsidiary Gaon Cable secures W120b ($90m) US AI data center cable deal
-
4
Iranian President Pezeshkian stated that Iran is ready to expand cooperation with Turkey to serve common interests and enhance regional security.
-
5
Global Business Forum Urges Business Leaders to Embrace AI and Rethink Strategies
-
6
Unlimit founder backs Phase blockchain with $45M as mainnet launches
-
7
Google and Microsoft's Q3 capital expenditure falls short of estimates, raising concerns about AI build-out costs and delays
-
8
Iran's Islamic Revolutionary Guard Corps claims to have shot down a US-made MQ-1 drone near the Strait of Hormuz.
-
9
Event prediction platform Kalshi completes $1 billion funding round, reaching a valuation of $40 billion, with non-sports revenue run rate exceeding $1 billion.
-
10
New ECB staff estimates show bond yield rise cutting 2027-28 growth by a cumulative 100 BPS and inflation by 90 BPS vs Sept baseline.
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
